Suchergebnisse - "Antibodies, Monoclonal, Humanized"

PubPharm (624)

1

A Case of Nephrotic Syndrome Induced by FOLFIRI plus Ramucirumab for Metastatic Descending Colon Cancer

enthalten in: Gan to kagaku ryoho. Cancer & chemotherapy | 2019

von Shingai, T. | Fukuzaki, T. | Okimura, S. | +8

2

Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

enthalten in: Cancer chemotherapy and pharmacology | 2019

von Suzuki, T. | Shinozaki, E. | Osumi, H. | +10

3

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer

enthalten in: British journal of cancer | 2017

von Codony-Servat, J. | Cuatrecasas, M. | Asensio, E. | +26

CommentIn: Br J Cancer. 2017 Dec 5;117(12):1733-1735. - PMID 29123265

4

Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab : An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Cascinu, S. | Rosati, G. | Nasti, G. | +49

5

Comparative pharmacokinetics, efficacy, and safety of bevacizumab biosimilar to reference bevacizumab in patients with metastatic colorectal cancer

enthalten in: Indian journal of cancer | 2017

von Apsangikar, P. | Chaudhry, S. | Naik, M. | +2

6

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer

enthalten in: The oncologist | 2017

von García-Carbonero, R. | van Cutsem, E. | Rivera, F. | +17

ErratumIn: Oncologist. 2017 Oct;22(10 ):1281. - PMID 29018169

7

FOLFOXIRI plus bevacizumab as conversion-therapy for liver metastases in colorectal cancer : A necessity?

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von Modest, D. | Neumann, U. | Pratschke, J.

CommentOn: Eur J Cancer. 2017 Mar;73:74-84. - PMID 27986363

8

Patients with Metastatic Colorectal Cancer and Hyperbilirubinemia Treated with FOLFIRI plus Bevacizumab as First-Line Treatment

enthalten in: Chemotherapy | 2017

von Huang, C. | Yeh, Y. | Ma, C. | +6

9

Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer

enthalten in: Oncology | 2017

von Larsen, F. | Markussen, A. | Nielsen, D. | +3

10

CEA response is associated with tumor response and survival in patients with KRAS exon 2 wild-type and extended RAS wild-type metastatic colorectal cancer receiving first-line FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial)

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Michl, M. | Stintzing, S. | Fischer von Weikersthal, L. | +20

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[63]